Significance of histologic molecular markers for prognosis of the ⅢA (N2) phase non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2014.03.013

Abstract

Abstract: Prognosis factors of ⅢA (N2) phase nonsmall cell lung cancer are various. The histological molecular markers are mainly about multiresistant gene, growth factors, mucin 4, insulinlike growth factor-2, Ki-67, PTEN and so on. Different expressions of these genes may divide the N2 non-small-cell lung cancer into different molecular subtypes, which is more effective to guide clinical therapy.

Key words: Histology, Biological markers, Neoplasm staging, Carcinoma, nonsmall cell lung, Prognosis

TANG Shi-Min, LI Wen-Hui, CHANG Li. Significance of histologic molecular markers for prognosis of the ⅢA (N2) phase non-small cell lung cancer[J]. Journal of International Oncology, 2014, 41(3): 203-205.

References

［1］ Detterbeck FC, Boffa DJ, Tanoue LT． The new lung cancer staging system［J］． Chest， 2009， 136(1)：260271．［2］ Nakagiri T， Sawabata N， Funaki S， et a1． Validation of pN2 subclassifications in patients with pathological stage ⅢA N2 nonsmall cell lung cancer［J］． Interact Cardiovasc Thorac Surg， 2011， 12(5)：733738．［3］ Li J， Li ZN， Yu LC， et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced nonsmall cell lung cancer who received neoadjuvant chemotherapy［J］. Lung Cancer， 2010， 69(1):116122. ［4］ Li J， Li ZN， Du YJ， et al. Expression of MRP1, BCRP, LRP, and ERC in Advanced NonSmallCell Lung Cancer:Correlation With Response to Chemotherapy and Survival［J］. Clin Lung Cancer， 2009， 10(6):414421. ［5］ Ikemura K, Yamamoto M, Miyazaki S， et al. MicroRNA145 posttranscriptionally regulates the expression and function of Pglycoprotein in intestinal epithelial cells［J］. Mol Pharmacol， 2013， 83(2):399405. ［6］ Zhang H, Shu H, Jiang W． Expression of PTEN, p53 and Pglycoprotein in nonsmall cell lung cancer and their predictive values［J］． Zhongguo Fei Ai Za Zhi， 2009， 12(11):12131216. ［7］ Huang JX，Li FY，Xiao W， et al. Expression of thymidylate synthase and glutathionestransferase pi in patients with esophageal squamous cell carcinoma［J］． World J Gastroenterol， 2009， 15(34):43164321. ［8］ Xu C， Feng D， Li L， et al． The expression and prognostic significance of ERCC1 and GSTpi in lung cancer［J］． Chin Lung Cancer， 2010， 13(3):195200．［9］ Mlak R, Krawczyk P, Ramlau R， et al． Predictive value of ERCC1 and RRM1 gene singlenucleotide polymorphisms for firstline platinumand gemcitabinebased chemotherapy in nonsmall cell lung cancer patients［J］． Oncol Rep， 2013， 30(5):23852398．［10］ Hubner RA， Riley RD， Billingham LJ， et al. Excision repair crosscomplementation group1 (ERCC1) status and lung cancer outcomes: a metaanalysis of published studies and recommendations［J］． PLoS One， 2011， 6(10):e25164．［11］ Ahn HK, Choi YL, Han JH， et al． Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive nonsmall cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery［J］． Lung Cancer， 2013， 79(3)：300306. ［12］ Sun HB, Ou W, Li Y， et al． Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced nonsmall cell lung cancer［J］． Clin Lung Cancer， 2013， 14(4)：376382. ［13］ Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation［J］．Brain Tumor Pathol， 2012， 29(2):7386. ［14］ Carrillo de Santa Pau E，Arias FC，Caso Peláez E，et al．Prognostic significance of the expression of vascular endothelial growth factors A，B，C，and D and their receptors R1，R2，and R3 in patients with non small cell lung cancer［J］． Cancer， 2009， 115(8):17011712. ［15］张连民，张真发，孙冰生，等. 黏蛋白4及胰岛素样生长因子2对ⅢA～N2期非小细胞肺癌预后的影响［J］．中华实验外科杂志， 2012， 29(11)：22302233. ［16］ Dowsett M, Nielsen TO, A′Hern R， et al． Assessment of ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group［J］． J Natl Cancer Inst， 2011， 103(22):16561664．［17］ Jakobsen JN, SantoniRugiu E, Ravn J， et al． Intratumour variation of biomarker expression by immunohistochemistry in resectable nonsmall cell lung cancer［J］． Eur J Cancer， 2013， 49(11)：24942503. ［18］ Singh M, Chaudhry P, Fabi F， et al． Cisplatininduced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance［J］． BMC Cancer， 2013， 13(1)：19．［19］ Wu HJ, Hao Q, Wang K， et al． Effects of PTEN gene on invasion and migration of ovarian cancer cell line A2780 and related mechanisms［J］． Zhonghua Zhong Liu Za Zhi， 2011， 33(3):165168．［20］ Panagiotou I, Georgiannos SN, Tsiambas E， et al． Impact of HER2 and PTEN Simultaneous Deregulation in Nonsmall Cell Lung Carcinoma: Correlation with Biological Behavior［J］． Asian Pac J Cancer Prev， 2012， 13(12):63116318. ［21］ Zhou L, Li Y, Zhou D， et al． Loss of Klotho contributes to kidney injury by derepression of Wnt/βcatenin signaling［J］． J Am Soc Nephrol， 2013， 24(5):771785．［22］ Ryuge S， Sato Y， Wang GQ， et al． Prognostic significance of nestin expression in resected nonsmall cell lung cancer［J］． Chest， 2011， 139(4):862869．

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.